NSE · Healthcare · Drug Manufacturers - General
EPS came in at 9.83 against a street estimate of 9.20 — a beat of 6.8%.
with an average price target of ₹2,304.67.
| Document | Date |
|---|---|
| Q1 FY27 earnings call CORONA REMEDIES LIMITED – Q1 FY27 EARNINGS SUMMARY --- HEADLINE NUMBERS • Revenue Q1 FY27: INR 422 crores vs INR 347 crores in Q1 FY26 = 21.9% YoY | 2026-08-10 |
| Quarterly results · Q1 FY27 CORONA REMEDIES LIMITED - Q1 FY27 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from operations Q1FY27: Rs 422.4 crores (21.9% YoY growth vs Rs 346.5 | 2026-08-07 |
| Investor presentation CORONA REMEDIES LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Q1 FY27 Revenue: INR 422.4 Crores, +21.9% Y-o-Y (vs IPM growth of 9.81%) • Q1 FY27 EBI | 2026-07-31 |
| Annual report FY2026 CORONA REMEDIES LIMITED - ANNUAL REPORT FY 2025-26 SUMMARY HEADLINE NUMBERS • REVENUE FROM OPERATIONS: ₹1,403.18 Crores (FY 2024-25: ₹1,196.42 Crore | 2026-06-15 |
| Q4 FY26 earnings call CORONA REMEDIES LIMITED - Q4 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue FY26: INR 1,403 crores vs INR 1,106 crores FY25 = 17.3% YoY growth • P | 2026-05-18 |
| Investor presentation · Q4 FY26 CORONA REMEDIES LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue: INR 1,403.2 Cr (+17.3% Y-o-Y), Q4 FY26: INR 353.1 Cr (+20.2% Y-o-Y) • FY | 2026-05-11 |
| Quarterly results · Q4 FY26 CORONA REMEDIES LIMITED - FY26 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹1,403.2 Cr in FY26 (up 17.3% YoY from ₹1,196.4 | 2026-05-11 |
| Q3 FY26 earnings call CORONA REMEDIES LIMITED – Q3 FY'26 SUMMARY HEADLINE NUMBERS • Q3 FY'26 Revenue: Rs. 342 crores (vs Rs. 298 crores Q3 FY'25) – 15% YOY growth • Q3 FY | 2026-02-10 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CORONA Remedies Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.